Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tezepelumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AMG 157

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            The NAVIGATOR trial met the primary endpoint with tezepelumab added to standard of care showing a significant and clinically meaningful reduction compared to placebo plus SoC in the annualized asthma exacerbation rate over 52 weeks in the overall patient population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenzilumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Humaneered

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: KPM Tech

            Deal Size: $20.0 million Upfront Cash: $6.0 million

            Deal Type: Licensing Agreement November 03, 2020

            Details:

            It is Humanigen's first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical and KPM Tech for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Treprostinil Sodium

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tyvaso

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            The presentation featured safety data from the phase 3 INCREASE study of Tyvaso, which showed that patients with PH-ILD receiving Tyvaso, vs those receiving placebo, experienced fewer exacerbations of underlying lung disease and an improvement in forced vital capacity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Treprostinil Sodium

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tyvaso

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            Details:

            The presentation will include data from the phase 3 INCREASE study of Tyvaso in patients with PH-ILD, which included an evaluation of the impact of Tyvaso on parameters on lung function measured by patients' forced vital capacity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option. Dupixent significantly reduced severe asthma attacks by up to 65% over one year compared to placebo .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gefapixant

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MK-7264

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            COUGH-1 and COUGH-2 are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Treprostinil Sodium

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LIQ861

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2020

            Details:

            The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Treprostinil Sodium

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tyvaso

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2020

            Details:

            FDA accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 11, 2020

            Details:

            Regeneron and Sanofi have commenced potentially registrational trials investigating Dupixent in a number of diseases driven in part by type 2 inflammation, including: COPD, Eosinophilic esophagitis, Prurigo nodularis, Chronic spontaneous urticaria and Bullous pemphigoid.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cefiderocol,Linezolid

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            FDA has accepted the company’s supplemental New Drug Application (sNDA) for FETROJA® (cefiderocol) and granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) date of September 27, 2020.

            PharmaCompass